Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
7.78
+0.75 (10.67%)
At close: Feb 20, 2026, 4:00 PM EST
7.64
-0.14 (-1.80%)
After-hours: Feb 20, 2026, 7:54 PM EST
Ocular Therapeutix Revenue
In the year 2025, Ocular Therapeutix had annual revenue of $51.95M, down -18.47%. Ocular Therapeutix had revenue of $13.25M in the quarter ending December 31, 2025, a decrease of -22.43%.
Revenue (ttm)
$51.95M
Revenue Growth
-18.47%
P/S Ratio
32.60
Revenue / Employee
$159,849
Employees
325
Market Cap
1.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.95M | -11.77M | -18.47% |
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
| Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
| Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
| Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
| Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
| Dec 31, 2014 | 772.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 10.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.06B |
| Monte Rosa Therapeutics | 181.54M |
| AnaptysBio | 169.47M |
| Intellia Therapeutics | 57.53M |
| uniQure | 15.75M |
| Capricor Therapeutics | 11.13M |
| Relay Therapeutics | 8.36M |
| Celldex Therapeutics | 2.60M |
OCUL News
- 1 day ago - Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 3 days ago - Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript - Seeking Alpha
- 3 days ago - Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - Reuters
- 7 days ago - Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - GlobeNewsWire
- 14 days ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive - Seeking Alpha
- 2 months ago - Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Benzinga
- 3 months ago - Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript - Seeking Alpha